CONTROVERSIES IN DETERMINATION OF EPOETIN (RECOMBINANT-HUMAN-ERYTHROPOIETIN) DOSAGES

被引：11

作者：

ABRAHAM, PA ^{[1
]}

STPETER, WL ^{[1
]}

REDICKILL, KA ^{[1
]}

HALSTENSON, CE ^{[1
]}

机构：

[1] UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA

来源：

CLINICAL PHARMACOKINETICS | 1992年 / 22卷 / 06期

关键词：

D O I：

10.2165/00003088-199222060-00001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

收藏

页码：409 / 415

页数：7

相关论文

共 48 条

[1] ABRAHAM PA, 1991, J AM SOC NEPHROL, V2, P927
[2] ANDROGENS POTENTIATE THE EFFECTS OF ERYTHROPOIETIN IN THE TREATMENT OF ANEMIA OF END-STAGE RENAL-DISEASE
BALLAL, SH
DOMOTO, DT
POLACK, DC
MARCIULONIS, P
MARTIN, KJ
[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1991, 17 (01) : 29 - 33
[3] BOMMER J, 1988, LANCET, V2, P406
[4] BOMMER J, 1991, CONTRIB NEPHROL, V88, P136
[5] HYPERTENSION FOLLOWING ERYTHROPOIETIN THERAPY IN ANEMIC HEMODIALYSIS-PATIENTS
BUCKNER, FS
ESCHBACH, JW
HALEY, NR
DAVIDSON, RC
ADAMSON, JW
[J]. AMERICAN JOURNAL OF HYPERTENSION, 1990, 3 (12) : 947 - 955
[6] EFFECT OF RECOMBINANT-HUMAN-ERYTHROPOIETIN THERAPY ON BLOOD-PRESSURE IN HEMODIALYSIS-PATIENTS
BURGESS, ED
[J]. AMERICAN JOURNAL OF NEPHROLOGY, 1991, 11 (01) : 23 - 26
[7] BENEFITS AND RISKS OF PROTRACTED TREATMENT WITH HUMAN RECOMBINANT ERYTHROPOIETIN IN PATIENTS HAVING HEMODIALYSIS
CASATI, S
PASSERINI, P
CAMPISE, MR
GRAZIANI, G
CESANA, B
PERISIC, M
PONTICELLI, C
[J]. BMJ-BRITISH MEDICAL JOURNAL, 1987, 295 (6605): : 1017 - 1020
[8] COTES PM, 1989, Q J MED, V70, P113
[9] LOW-DOSE RECOMBINANT-HUMAN-ERYTHROPOIETIN THERAPY IN CHRONIC-HEMODIALYSIS PATIENTS
DUFF, DR
GOLPER, TA
SLOAN, RS
BRIER, ME
ARONOFF, GR
[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1991, 18 (01) : 60 - 64
[10] DRUG-THERAPY - ERYTHROPOIETIN
ERSLEV, AJ
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (19) : 1339 - 1344

← 1 2 3 4 5 →